Urinary Urea, Uric Acid and Hippuric Acid as Potential Biomarkers in Multiple Sclerosis Patients

被引：11
作者：
Atya H.B. [1 ]
Ali S.A. [1 ]
Hegazy M.I. [2 ]
El Sharkawi F.Z. [1 ]
机构：
[1] Biochemistry Department, Faculty of Pharmacy, Helwan University, Cairo
[2] Neurology Department, Faculty of Medicine, Cairo University, Cairo
来源：
Indian Journal of Clinical Biochemistry | 2018年 / 33卷 / 2期
关键词：
Hippuric acid; Multiple sclerosis; Urea; Uric acid; Urinary;
D O I：
10.1007/s12291-017-0661-6
中图分类号：
学科分类号：
摘要：
Urine is a proven source of metabolite biomarkers and has the potential to be a rapid, noninvasive, inexpensive, and efficient diagnostic tool for various human diseases. Despite these advantages, urine is an under-investigated source of biomarkers for multiple sclerosis (MS). The objective was to investigate the level of some urinary metabolites (urea, uric acid and hippuric acid) in patients with MS and correlate their levels to the severity of the disease, MS subtypes and MS treatment. The urine samples were collected from 73 MS patients-48 with RRMS and 25 with SPMS- and age matched 75 healthy controls. The values of urinary urea, uric acid and hippuric acid in MS patients were significantly decreased, and these metabolites in SPMS pattern showed significantly decrease than RRMS pattern. Also showed significant inverse correlation with expanded disability status scale and number of relapses. Accordingly, they may act as a potential urinary biomarkers for MS, and correlate to disease progression. © 2017, Association of Clinical Biochemists of India.
引用
收藏
页码：163 / 170
页数：7
相关论文
共 51 条
  • [1] Sospedra M., Martin R., Immunology of multiple sclerosis, Annu Rev Immunol, 23, pp. 683-747, (2005)
  • [2] Miller E., Walczak A., Saluk J., Ponczek M.B., Majsterek I., Oxidative modification of patient’s plasma proteins and its role in pathogenesis of multiple sclerosis, Clin Biochem, 45, 1-2, pp. 26-30, (2012)
  • [3] Tremlett H., van der Mei I.A., Pittas F., Blizzard L., Paley G., Mesaros D., Et al., Monthly ambient sunlight, infections and relapse rates in multiple sclerosis, Neuroepidemiology, 31, 4, pp. 271-279, (2008)
  • [4] Marrie R.A., Cohen J.A., Interferons in secondary progressive multiple sclerosis, in multiple sclerosis therapeutics, (2007)
  • [5] Gebregiworgis T., Massilamany C., Gangaplara A., Thulasingam S., Kolli V., Werth M.T., Et al., The potential of urinary metabolites for diagnosing multiple sclerosis, ACS Chem Biol, 8, 4, pp. 684-690, (2013)
  • [6] Lourenco A.S., Baldeiras I., Graos M., Duarte C.B., Proteomics-based technologies in the discovery of biomarkers for Multiple Sclerosis in the cerebrospinal fluid, Curr Mol Med, 11, 4, pp. 326-349, (2011)
  • [7] Bielekova B., Martin R., Development of biomarkers in multiple sclerosis, Brain, 127, pp. 1463-1478, (2004)
  • [8] Dobson R., Urine: an under-studied source of biomarkers in multiple sclerosis?, Mult Scler Relat Disord, 1, 2, pp. 76-80, (2012)
  • [9] Gholipour T., Ghazizadeh T., Babapour S., Mansouri B., Ghafarpour M., Siroos B., Et al., Decreased urinary level of melatonin as a marker of disease severity in patients with multiple sclerosis, Iran J Allergy Asthma Immunol, 14, 1, pp. 91-97, (2015)
  • [10] Rejdak K., Leary S.M., Petzold A., Thompson A.J., Miller D.H., Giovannoni G., Urinary neopterin and nitric oxide metabolites as markers of interferon beta-1a activity in primary progressive multiple sclerosis, Mult Scler, 16, 9, pp. 1066-1072, (2010)
123456